Mathai Mammen, head of R&D for J&J’s Janssen unit (Rob Tannenbaum)
As J&J moves to split its business, execs lay out future R&D focus — and tout megablockbuster potential
Last week, J&J took a step familiar to other pharma conglomerates in spinning out its consumer business to focus on R&D, but offered few …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
